Steven J Kiddle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9264632/publications.pdf

Version: 2024-02-01

43 papers	4,520 citations	394421 19 h-index	361022 35 g-index
49 all docs	49 docs citations	49 times ranked	8964 citing authors

#	Article	IF	Citations
1	Accelerated FEV₁decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. European Respiratory Journal, 2021, 57, 2000918.	6.7	24
2	Challenges and Pitfalls of Using Repeat Spirometry Recordings in Routine Primary Care Data to Measure FEV1 Decline in a COPD Population. Journal of Pragmatic and Observational Research, 2021, Volume 12, 119-130.	1.5	0
3	Î²-Secretase1 biological markers for Alzheimerâ€™s disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	6.2	16
4	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	3.1	18
5	Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease . International Journal of COPD, 2020, Volume 15, 3079-3091.	2.3	15
6	Prediction of five-year mortality after COPD diagnosis using primary care records. PLoS ONE, 2020, 15, e0236011.	2.5	6
7	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
8	Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases. Cells, 2020, 9, 665.	4.1	18
9	Prediction of five-year mortality after COPD diagnosis using primary care records. , 2020, 15, e0236011.		0
10	Prediction of five-year mortality after COPD diagnosis using primary care records. , 2020, 15, e0236011.		0
11	Prediction of five-year mortality after COPD diagnosis using primary care records. , 2020, 15, e0236011.		0
12	Prediction of five-year mortality after COPD diagnosis using primary care records. , 2020, 15, e0236011.		0
13	Inhaled corticosteroids, blood eosinophils, and FEV₁ decline in patients with COPD in a large UK primary health care setting . International Journal of COPD, 2019, Volume 14, 1063-1073.	2.3	14
14	Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review. Respiratory Research, 2019, 20, 277.	3.6	8
15	Characteristics, service use, and mortality of clusters of multimorbid patients in England: a population-based study. Lancet, The, 2019, 394, S102.	13.7	4
16	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimerâ€™s disease risk. Nature Genetics, 2019, 51, 404-413.	21.4	1,625
17	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimerâ€™s disease. Dialogues in Clinical Neuroscience, 2019, 21, 177-191.	3.7	17
18	A Blood Test for Alzheimerâ€™s Disease: Progress, Challenges, and Recommendations. Journal of Alzheimer's Disease, 2018, 64, S289-S297.	2.6	15

#	Article	IF	Citations
19	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	3.4	28
20	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652.	10.1	434
21	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. Journal of Alzheimer's Disease, 2016, 52, 561-572.	2.6	41
22	Alzheimer's disease: are blood and brain markers related? A systematic review. Annals of Clinical and Translational Neurology, 2016, 3, 455-462.	3.7	14
23	Genetic Risk as a Marker of Amyloid-Î² and Tau Burden in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1417-1427.	2.6	16
24	Blood metabolite markers of neocortical amyloid-Î² burden: discovery and enrichment using candidate proteins. Translational Psychiatry, 2016, 6, e719-e719.	4.8	26
25	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	2.6	2
26	Blood Protein Markers of Neocortical Amyloid-Î² Burden: A Candidate Study Using SOMAscan Technology. Journal of Alzheimer's Disease, 2015, 46, 947-961.	2.6	49
27	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimerâ€™s Disease Diagnosis. Journal of Alzheimer's Disease, 2015, 49, 659-669.	2.6	43
28	Circulating Proteomic Signatures of Chronological Age. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 809-816.	3.6	106
29	Plasma protein biomarkers of Alzheimerâ€™s disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Translational Psychiatry, 2015, 5, e584-e584.	4.8	39
30	Blood protein predictors of brain amyloid for enrichment in clinical trials?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 48-60.	2.4	50
31	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimerâ€™s Disease. PLoS ONE, 2015, 10, e0134368.	2.5	26
32	Wigwams: identifying gene modules co-regulated across multiple biological conditions. Bioinformatics, 2014, 30, 962-970.	4.1	36
33	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.8	182
34	P1-166: DISTINCT BLOOD PROTEIN MARKERS ARE ASSOCIATED WITH BRAIN REGIONS OF EARLY AMYLOID DEPOSITION IN ALZHEIMER'S DISEASE. , 2014, 10, P360-P361.		0
35	P3-113: NOVEL CANDIDATE BLOOD PROTEOME MARKERS OF ALZHEIMER'S DISEASE BRAIN AMYLOID BURDEN: A MULTIPLEX TMT-LC/MS-MS DISCOVERY APPROACH. , 2014, 10, P669-P670.		0
36	F5-02-02: DISTINCT BLOOD PROTEIN MARKERS ARE ASSOCIATED WITH GLOBAL AND REGIONAL BRAIN BETA-AMYLOID DEPOSITION IN ALZHEIMER'S DISEASE. , 2014, 10, P283-P283.		0

#	Article	IF	Citations
37	P1-008: BLOOD-BASED BIOMARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND COGNITIVE DECLINE IN NON-DEMENTED ELDERLY. , 2014, 10, P307-P307.		0
38	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. Journal of Alzheimer's Disease, 2013, 38, 515-531.	2.6	160
39	MEDIATOR25 Acts as an Integrative Hub for the Regulation of Jasmonate-Responsive Gene Expression in Arabidopsis Â Â. Plant Physiology, 2012, 160, 541-555.	4.8	207
40	Arabidopsis Defense against Botrytis cinerea: Chronology and Regulation Deciphered by High-Resolution Temporal Transcriptomic Analysis Â Â. Plant Cell, 2012, 24, 3530-3557.	6.6	337
41	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	2.5	89
42	High-Resolution Temporal Profiling of Transcripts during Arabidopsis Leaf Senescence Reveals a Distinct Chronology of Processes and Regulation Â Â. Plant Cell, 2011, 23, 873-894.	6.6	776
43	Temporal clustering by affinity propagation reveals transcriptional modules in Arabidopsis thaliana. Bioinformatics, 2010, 26, 355-362.	4.1	58